Incorporation of prognostic and predictive factors into glioma clinical trials

Derek R. Johnson, Evanthia Galanis

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Treatment of brain tumors is increasingly informed by biomarkers that predict patient prognosis and response to therapy. While this progress represents a great opportunity for the field of neuro-oncology, it also presents significant challenges. Biomarkers are not straightforward to identify, and previously used clinical trial paradigms are poorly suited to the task of identifying treatments effective only in selected subsets of patients. Unless investigators adapt new tools and procedures that better account for the biological diversity of gliomas, future clinical trials run the dual risk of missing important treatment effects and exposing patients to interventions destined to prove ineffective for their tumors. In this article, we will review the progress made in the past decade with respect to biomarkers in neuro-oncology, address barriers to ongoing progress, and discuss clinical trial designs that may prove useful in moving neuro-oncology fully into the era of personalized medicine.

Original languageEnglish (US)
Pages (from-to)56-63
Number of pages8
JournalCurrent Oncology Reports
Volume15
Issue number1
DOIs
StatePublished - Feb 2013

Fingerprint

Glioma
Clinical Trials
Biomarkers
Precision Medicine
Biodiversity
Therapeutics
Brain Neoplasms
Research Personnel
Neoplasms

Keywords

  • Biomarker
  • Brain tumor
  • Clinical trial
  • Glioblastoma
  • Glioma
  • Predictive
  • Prognostic

ASJC Scopus subject areas

  • Oncology

Cite this

Incorporation of prognostic and predictive factors into glioma clinical trials. / Johnson, Derek R.; Galanis, Evanthia.

In: Current Oncology Reports, Vol. 15, No. 1, 02.2013, p. 56-63.

Research output: Contribution to journalArticle

@article{b34fefb9c6a54ba3a7523610e5e0896b,
title = "Incorporation of prognostic and predictive factors into glioma clinical trials",
abstract = "Treatment of brain tumors is increasingly informed by biomarkers that predict patient prognosis and response to therapy. While this progress represents a great opportunity for the field of neuro-oncology, it also presents significant challenges. Biomarkers are not straightforward to identify, and previously used clinical trial paradigms are poorly suited to the task of identifying treatments effective only in selected subsets of patients. Unless investigators adapt new tools and procedures that better account for the biological diversity of gliomas, future clinical trials run the dual risk of missing important treatment effects and exposing patients to interventions destined to prove ineffective for their tumors. In this article, we will review the progress made in the past decade with respect to biomarkers in neuro-oncology, address barriers to ongoing progress, and discuss clinical trial designs that may prove useful in moving neuro-oncology fully into the era of personalized medicine.",
keywords = "Biomarker, Brain tumor, Clinical trial, Glioblastoma, Glioma, Predictive, Prognostic",
author = "Johnson, {Derek R.} and Evanthia Galanis",
year = "2013",
month = "2",
doi = "10.1007/s11912-012-0279-z",
language = "English (US)",
volume = "15",
pages = "56--63",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Incorporation of prognostic and predictive factors into glioma clinical trials

AU - Johnson, Derek R.

AU - Galanis, Evanthia

PY - 2013/2

Y1 - 2013/2

N2 - Treatment of brain tumors is increasingly informed by biomarkers that predict patient prognosis and response to therapy. While this progress represents a great opportunity for the field of neuro-oncology, it also presents significant challenges. Biomarkers are not straightforward to identify, and previously used clinical trial paradigms are poorly suited to the task of identifying treatments effective only in selected subsets of patients. Unless investigators adapt new tools and procedures that better account for the biological diversity of gliomas, future clinical trials run the dual risk of missing important treatment effects and exposing patients to interventions destined to prove ineffective for their tumors. In this article, we will review the progress made in the past decade with respect to biomarkers in neuro-oncology, address barriers to ongoing progress, and discuss clinical trial designs that may prove useful in moving neuro-oncology fully into the era of personalized medicine.

AB - Treatment of brain tumors is increasingly informed by biomarkers that predict patient prognosis and response to therapy. While this progress represents a great opportunity for the field of neuro-oncology, it also presents significant challenges. Biomarkers are not straightforward to identify, and previously used clinical trial paradigms are poorly suited to the task of identifying treatments effective only in selected subsets of patients. Unless investigators adapt new tools and procedures that better account for the biological diversity of gliomas, future clinical trials run the dual risk of missing important treatment effects and exposing patients to interventions destined to prove ineffective for their tumors. In this article, we will review the progress made in the past decade with respect to biomarkers in neuro-oncology, address barriers to ongoing progress, and discuss clinical trial designs that may prove useful in moving neuro-oncology fully into the era of personalized medicine.

KW - Biomarker

KW - Brain tumor

KW - Clinical trial

KW - Glioblastoma

KW - Glioma

KW - Predictive

KW - Prognostic

UR - http://www.scopus.com/inward/record.url?scp=84872370490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872370490&partnerID=8YFLogxK

U2 - 10.1007/s11912-012-0279-z

DO - 10.1007/s11912-012-0279-z

M3 - Article

VL - 15

SP - 56

EP - 63

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 1

ER -